Novartis Pharmaceutical Plant – Phase 3 Expansion

C2D Solutions is excited to announce our involvement in the expansion of Novartis’ biopharmaceutical manufacturing facility in Singapore. In collaboration with Exyte Singapore, our team provides comprehensive mechanical engineering consultancy services to support this significant project.

The project will incorporate advanced digitalization and automation technologies to boost manufacturing productivity and upskill the workforce. The expanded facility is scheduled to become operational in 2026 and will focus on producing therapeutic antibody drugs for patients worldwide.

Our role involves ensuring the building’s mechanical systems integrate seamlessly with Novartis’ state-of-the-art technologies to protect both personnel and infrastructure.  We are honored to contribute to a project that enhances Singapore’s position as a leading hub in the biopharmaceutical industry.

This collaboration highlights our commitment to delivering engineering excellence in the pharmaceutical sector. We look forward to the successful completion of this expansion and the positive impact it will have on global healthcare.

News References:

Fierce Pharma